Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.

Saved in:
Bibliographic Details
Title: Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.
Authors: Cohen GL; Mary Potter Oncology Center, Life Groenkloof Hospital, Pretoria, South Africa. Electronic address: glcresearch@mpoc.co.za., Coetzee C; Cape Town Oncology Trials, Cape Town, South Africa. Electronic address: corlia.coetzee@ctot.co.za., Walton CA; Bay Oncology, Gqeberha, South Africa. Electronic address: admin@bayoncology.co.za., Reig Torras Ò; Department of Medical Oncology and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain. Electronic address: oreig@clinic.cat., Chul Cho B; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: CBC1971@yuhs.ac., McAdam G; Cancercare Rondebosch Oncology-Clinical Trials, Cape Town, South Africa. Electronic address: georgina.mcadam@cancercare.co.za., Rojas CI; Department Medical Oncology, Bradford Hill Centro de Investigación Clínica, Santiago, Chile. Electronic address: cirojas@bradfordhill.cl., Medina Rodríguez L; Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address: laura.medina@ibima.eu., Papai Z; Department of Oncology, Hungarian Defense Forces Medical Center, Budapest, Hungary. Electronic address: trial.zspapai@gmail.com., Chan SW; Clinical Trial Research Unit, Sandton Oncology Medical Group, Sandton, South Africa. Electronic address: drchan@sandtononcology.co.za., Rapoport BL; The Medical Oncology Centre of Rosebank, Clinical and Translational Research Unit (CTRU), Saxonwold, South Africa and Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. Electronic address: brapoport@rosebankoncology.co.za., Caglevic C; Cancer Research Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile. Electronic address: christian.caglevic@falp.org., Yañez Weber P; Universidad de La Frontera, James Lind Centro de Investigación del Cáncer, Temuco, Chile. Electronic address: pyanez@jameslind.cl., Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Electronic address: t.takahashi@scchr.jp., Kurata T; Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan. Electronic address: kurata.tak@kmu.ac.jp., Song G; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: gina.song@merck.com., Cohen JW; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: julia.cohen@merck.com., Akala OO; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: omobolaji.akala@merck.com., Khanyile R; Medical Oncology, Outpatient Department, Steve Biko Academic Hospital, Pretoria, South Africa. Electronic address: richard.khanyile@up.ac.za.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Nov 17; Vol. 230, pp. 115709. Date of Electronic Publication: 2025 Aug 09.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115709